Emergent BioSolutions (EBS) EBT Margin Growth (1y) (2012 - 2026)

Emergent BioSolutions (EBS) EBT Margin Growth (1y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (1y) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 342.00
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -166.00
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -5,404.00
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1,258.00
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 8,812.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2,773.00
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 132.00
10 Emergent BioSolutions 389.77 Mn 228.27 Mn 84.10 Mn -3,313.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -3,313.00
Dec 31, 2025 -1,992.00
Sep 30, 2025 -2,354.00
Jun 30, 2025 52,768.00
Mar 31, 2025 3,769.00
Dec 31, 2024 553.00
Sep 30, 2024 14,677.00
Jun 30, 2024 -46,555.00
Mar 31, 2024 10,178.00
Dec 31, 2023 -111.00
Sep 30, 2023 -7,029.00
Jun 30, 2023 -3,992.00
Mar 31, 2023 -9,650.00
Dec 31, 2022 -5,357.00
Sep 30, 2022 -1,212.00
Jun 30, 2022 -3,604.00
Mar 31, 2022 -2,385.00
Dec 31, 2021 -920.00
Sep 30, 2021 -3,017.00
Jun 30, 2021 -2,867.00